2.07 USD
▲+0.04+6.70%
盘后 1.95 +0.48%
2026-08-03
市值
$359.31M
市盈率
—
EPS
-0.23
股息率
—
52 周区间
0.53 – 2.86
成交量
1.65M
Beta
1.51
目标价
10.22
52W 低 0.5352W 高 2.86
价格走势
公司简介
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn’s disease. The company has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and co...